http://www.aktiencheck.de aktiencheck.de aktiencheck.de Thu, 14 May 2026 16:02:30 +0200 2 http://www.aktiencheck.de/forum/Alzamend_Neuro_die_naechste_Alzheimeraktie-A4189B-t576186 http://www.aktiencheck.de/forum/Alzamend_Neuro_die_naechste_Alzheimeraktie-A4189B-t576186 expect topline data in June 2023, AL001 recently completed the clinical portion of Phase IIA trials and expect topline data in June 2023. Our second candidate, ALZN002, is a patented method using a mutant peptide sensitized cell as a cell-based therapeutic vaccine which seeks to restore the ability of the patient’s immunological system to combat AD. [<a href="http://www.aktiencheck.de/forum/Alzamend_Neuro_die_naechste_Alzheimeraktie-A4189B-t576186">mehr</a>]